Search Results - "Leuw, Philipp"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
  2. 2
  3. 3

    Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in Europe by Schuettfort, Gundolf, Cabello, Alfonso, Cotter, Aoife G, Leuw, Philipp D E, Górgolas, Miguel, Hamzah, Lisa, Herrmann, Eva, Kann, Gerrit, Khaykin, Pavel, Mena, Alvaro, Stephan, Christoph, Haberl, Annette E

    Published in AIDS patient care and STDs (01-04-2021)
    “…The choice of an optimal antiretroviral therapy (ART) in naive patients presenting late for initial therapy with advanced HIV infection, that is, with a CD4…”
    Get more information
    Journal Article
  4. 4

    HLA‐B57.01 shields people living with HIV for significantly better periodontal health by Schuettfort, Gundolf, Leuw, Philipp, Haberl, Annette, Herrmann, Eva, Park, Kyu‐Hyun, Wolf, Timo, Stephan, Christoph

    Published in Journal of periodontology (1970) (01-08-2018)
    “…Background To assess the association between HLA‐B57.01 (Human leukocyte antigen) and clinical parameters of chronic periodontitis in people living with HIV…”
    Get full text
    Journal Article
  5. 5

    HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy by Donath, Maximilian, Wolf, Timo, Stürmer, Martin, Herrmann, Eva, Bickel, Markus, Khaykin, Pavel, Göpel, Siri, Gute, Peter, Haberl, Annette, de Leuw, Philipp, Schüttfort, Gundolf, Berger, Annemarie, Stephan, Christoph

    Published in Medical microbiology and immunology (01-12-2016)
    “…There are concerns about central nervous system (CNS)-replication of HIV-1 in patients on boosted protease inhibitors. Purpose of this study was to compare…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Was bei der Betreuung von HIV-Infizierten zu beachten ist by Kann, Gerrit, de Leuw, Philipp

    Published in MMW Fortschritte der Medizin (01-06-2023)
    “…An Wechselwirkungen denken Menschen mit HIV-Infektion erhalten in der Regel eine antiretrovirale Therapie (ART). Mögliche Wechselwirkungen mit der…”
    Get full text
    Journal Article
  10. 10

    Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir by Weirauch, Tobias, Burger, Gerrit, Cadar, Dániel, Gabriel, Martin, Koepsell, Julia, Schüttfort, Gundolf, de Leuw, Philipp, Bickel, Markus, Vehreschild, Maria J.G.T., Wolf, Timo, Wetzstein, Nils

    “…•Immunosuppressed patients increasingly engage in travel activity to the tropics.•B-cell depletion is a risk factor for complications after Yellow fever (YF)…”
    Get full text
    Journal Article
  11. 11

    Influence of tenofovir exposure in utero on primary dentition by Schüttfort, Gundolf, Höfler, Stephan, Kann, Gerrit, Königs, Christoph, de Leuw, Philipp, Herrmann, Eva, Stephan, Christoph, Haberl, Annette

    Published in European journal of pediatrics (01-11-2020)
    “…Tenofovir disoxoproxil fumarate (TDF) is recommended for antiretroviral treatment for pregnant women living with HIV. As a comparative method to study bone…”
    Get full text
    Journal Article
  12. 12

    Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiation by Kann, Gerrit, Wetzstein, Nils, Bielke, Hannah, Schuettfort, Gundolf, Haberl, Annette E., Wolf, Timo, Kuepper-Tetzel, Claus P., Wieters, Imke, Kessel, Johanna, de Leuw, Philipp, Bickel, Markus, Khaykin, Pavel, Stephan, Christoph

    Published in The Journal of infection (01-09-2021)
    “…Summary HIV-infected patients with Pneumocystis-pneumonia (PCP) may develop paradoxical immune reconstitution inflammatory syndrome (IRIS), when combination…”
    Get full text
    Journal Article
  13. 13

    How to use virological tools for the optimal management of chronic hepatitis C by de Leuw, Philipp, Sarrazin, Christoph, Zeuzem, Stefan

    Published in Liver international (01-01-2011)
    “…Approximately 180 million individuals are chronically infected with hepatitis C, which is strongly associated with the development of cirrhosis, end‐stage…”
    Get full text
    Journal Article
  14. 14

    Protease inhibitors for the treatment of hepatitis C virus infection by de Leuw, Philipp, Stephan, Christoph

    Published in GMS infectious diseases (2017)
    “…The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25-30% of patients in Europe…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis: e0140525 by Schulze, Kornelius, Weismueller, Tobias J, Bubenheim, Michael, Huebener, Peter, Zenouzi, Roman, Lenzen, Henrike, Rupp, Christian, Gotthardt, Daniel, Leuw, Philipp de, Teufel, Andreas

    Published in PloS one (01-10-2015)
    “…Background & Aims Current guidelines recommend immunosuppressive treatment (IT) in patients with primary sclerosing cholangitis (PSC) and elevated…”
    Get full text
    Journal Article
  17. 17